IDVOther than small business
IDC (multiple-award IDV) HHSN271201700011IMASSACHUSETTS DEPARTMENT OF REVENUE
Overview
Award facts
- Orders under this IDV
- No orders recorded under this IDV.
- Period of performance
- From Apr 17, 2018
- Modifications
- 1
- Latest action Apr 17, 2018
- Contract type
- IDC (multiple-award IDV)
- PIID HHSN271201700011I
Description of requirement
IGF::OT::IGF PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Dates and value
- Award date
- Signed on Mar 31, 2017
- Ordering period ends
- Mar 31, 2022
- Ceiling
- Shared program ceiling (all awardees of this multiple-award vehicle, not a per-awardee value): $24,598,861
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Apr 17, 2018. View on USAspending · Recipient on SAM.gov
Recipient
LocationBOSTON, MA
UEINADGLWMAZDF6
CAGE code3LEX0
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeUS government entity
Parent companyTHE COMMONWEALTH OF MASSACHUSETTS
Business types and certifications
U.S. government entity
Self-reported at the time of the action.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NIDA
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NATIONAL INSTITUTES OF HEALTH NCATS
- Funded from
- 075-0875Federal accounts (agency financial reports)
Classification and competition
Classification
- Product or service (PSC)
- AN11R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH) (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Order dependent (IDV allows pricing arrangement to be determined separately for each order)1
- Offers received
- 10
Solicitation and notices
- Solicitation ID
- N01TR172001(as reported)
Contract details
- Subcontracting plan
- Individual subcontract planF
- Major program
- Cro support for ncats drug substance development and manufacture
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial item procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Transaction history
Modification history
- Base award
- Mar 31, 2017Base obligation at award: $5,000
- Latest action
- Apr 17, 2018 — Other administrative actionModification 1; obligation change -$5,000; administrative: no change in scope or value
- Actions by type
- Base award1
- Other administrative action1
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- Other U.S. entity (e.g. government)B
Structure
- Award or IDV
- IDV
- IDV type
- IDCB
- Indefinite-delivery contract type
- Indefinite delivery / indefinite quantityB
- Multiple or single award
- Multiple awardM
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N950
- Transactions recorded under this award key
- 2
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N95C
- Treasury accounts
- 075-2017/2017-0875-000
- Object classes
- 25.5: Research and development contracts